Betametasone as postoperative pain treatment for knee arthroscopies at a day surgical center

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2009-014717-27-SE

Enrollment

203

Registered

2009-07-23

Start date

2009-12-22

Completion date

Unknown

Last updated

2013-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unspecified knee pain investigated by an arthroscopy

Interventions

Trade Name: Betapred (Betametason) Product Name: Betapred Pharmaceutical Form: Injection*

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients going through knee surgery in a day surgical setting Patients should be classified either as ASA I or II to be eligible (ASA=American Society of Anesthesiologists) Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Patients going through repair of ligaments will be excluded Patients unable to understand the protocol Patients with diabetes Patients with coagulopathies Patients with atrial arryhtmias Patients < 18 years of age Patients on coticosteroids or NSAIDS two days ahead of surgery Patients who are pregnant

Design outcomes

Primary

Measure	Time frame
Main Objective: To investigate whether the addendum of betametason preoperatively will lower the perception of pain according to a verbal scale after knee surgery in a day surgical setting. Betametason is commonly given as an antiemetic. There is some evidence that betametason could have some impact on the level of postoperative pain.;Secondary Objective: To investigate whether the addendum of betametason preoperatively will lower the perception of pain according to a verbal and a visual analogue scale (VAS) after knee surgery in a day surgical setting. ;Primary end point(s): To investigate whether the addendum of betametason preoperatively will lower the perception of pain according to a verbal scale after knee surgery in a day surgical setting.	—

Measure

Time frame

Main Objective: To investigate whether the addendum of betametason preoperatively will lower the perception of pain according to a verbal scale after knee surgery in a day surgical setting. Betametason is commonly given as an antiemetic. There is some evidence that betametason could have some impact on the level of postoperative pain.;Secondary Objective: To investigate whether the addendum of betametason preoperatively will lower the perception of pain according to a verbal and a visual analogue scale (VAS) after knee surgery in a day surgical setting. ;Primary end point(s): To investigate whether the addendum of betametason preoperatively will lower the perception of pain according to a verbal scale after knee surgery in a day surgical setting.

—

Countries

Sweden

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026